This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

Order Online

When Emergency Control of SE Is Needed2 ... Consider Nembutal ®

Order Online 2017-05-03T06:26:10+00:00

AkornCSOS

APPROVED HEALTHCARE FACILITIES INSTRUCTIONS:

Download step by step instruction here

Step 1. Prepare to use AkornDirect.com CSOS

Before using the system, you will need the following:

  • CSOS Certificate* — To apply for a CSOS Certificate, visit the DEA E-commerce website http://www.deaecom.gov/applycert.html and follow the on-screen instructions
  • Akorn Direct Customer Account — An account can be obtained or verified by contacting

 

Step 2. Submit your Controlled Substance Online Order

Once you meet the requirements above, you are ready to place your order online with the AkornDirect.com CSOS ordering system.

ADloginCallouts

PLEASE NOTE: When ordering Nembutal® Sodium Solution (pentobarbital sodium injection, USP), Nembutal® must be the ONLYproduct in your cart.
DO NOT combine other products with this order.

 

Step 3. Follow the Step-by-Step Online Instructions

 The AkornDirect.com CSOS system will step you through the following screens to complete your order:

  • Checkout Process—Enter contact information, special delivery instructions, and a unique 6-digit identification number
  • Confirmation Process—Review your DEA e222 Form and upload your DEA CSOS electronic certificate
  • Approval Process—Wait for DEA e222 verification

For detailed ordering instructions, system requirements and to learn how to use Akorn CSOS, visit akorndirect.com/csos-setup.php

 

* A CSOS Certificate is a digital identity issued by the DEA’s CSOS Certification Authority that allows for electronic ordering of controlled substances.

 

See full prescribing information

Important Safety Information

CONTRAINDICATIONS
Barbiturates are contraindicated in patients with known barbiturate sensitivity. Barbiturates are also contraindicated in patients with a history of manifest or latent porphyria.

WARNINGS
1. Habit forming: Barbiturates may be habit forming. Tolerance, psychological and physical dependence may occur with continued use. Patients who have psychological dependence on barbiturates may increase the dosage or decrease the dosage interval without consulting a physician and may subsequently develop a physical dependence on barbiturates.

To minimize the possibility of overdosage or the development of dependence, the prescribing and dispensing of sedative-hypnotic barbiturates should be limited to the amount required for the interval until the next appointment. Abrupt cessation after prolonged use in the dependent person may result in withdrawal symptoms, including delirium, convulsions, and possibly death. Barbiturates should be withdrawn gradually from any patient known to be taking excessive dosage over long periods of time.

2. IV administration: Too rapid administration may cause respiratory depression, apnea, laryngospasm, or vasodilation with fall in blood pressure.
3. Acute or chronic pain: Caution should be exercised when barbiturates are administered to patients with acute or chronic pain, because paradoxical excitement could be induced or important symptoms could be masked. However, the use of barbiturates as sedatives in the postoperative surgical period and as adjuncts to cancer chemotherapy is well established.

4. Use in pregnancy: Barbiturates can cause fetal damage when administered to a pregnant woman. Retrospective, case-controlled studies have suggested a connection between the maternal consumption of barbiturates and a higher than expected incidence of fetal abnormalities.

Withdrawal symptoms occur in infants born to mothers who receive barbiturates throughout the last trimester of pregnancy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

5. Synergistic effects: The concomitant use of alcohol or other CNS depressants may produce additive CNS depressant effects.

ADVERSE REACTIONS

The following adverse reactions and their incidence were compiled from surveillance of thousands of hospitalized patients. Because such patients may be less aware of certain of the milder adverse effects of barbiturates, the incidence of these reactions may be somewhat higher in fully ambulatory patients.

More than 1 in 100 patients. The most common adverse reaction estimated to occur at a rate of 1 to 3 patients per 100 is: Nervous System: Somnolence.

Less than 1 in 100 patients. Adverse reactions estimated to occur at a rate of less than 1 in 100 patients listed below, grouped by organ system, and by decreasing order of occurrence are:

Nervous system: Agitation, confusion, hyperkinesia, ataxia, CNS depression, nightmares, nervousness, psychiatric disturbance, hallucinations, insomnia, anxiety, dizziness, thinking abnormality.

Respiratory system: Hypoventilation, apnea.

Cardiovascular system: Bradycardia, hypotension, syncope.

Digestive system: Nausea, vomiting, constipation.

Other reported reactions: Headache, injection site reactions, hypersensitivity reactions (angioedema, skin rashes, exfoliative dermatitis), fever, liver damage, megaloblastic anemia following chronic phenobarbital use.

Please see Nembutal full prescribing information.